|
|
Article: Cambria Biosciences' Chemical Genetics Platform is Featured in Nature Article Describing a New Pharmaceutical Mode of Action.
- Article from:
- Business Wire
- Article date:
- March 13, 2008
|
Copyright informationCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Research collaboration identifies novel nematode nicotinic receptor -
WOBURN, Mass. -- Cambria Biosciences, a privately held biopharmaceutical company, today announced that it has co-authored an article with partner Novartis Animal Health Inc. which was published in the March 13 edition of Nature. The study describes Novartis' discovery of a new anthelmintic compound effective against parasitic nematode strains resistant to currently available treatments. Its unique mode of action was elucidated by Cambria's chemical genetics platform, which identified a nematode-specific protein whose biological function had not been previously studied. This successful work also led to ...
Related newspaper, magazine, and journal articles:
|
|
Article: The EU's Animal Health Policy Strategy.
Mondaq Business Briefing;
January 16, 2007 ;
700+ words
......of its evaluation of the Community's Animal Health Policy ( CAHP ) at a conference in...conference feedback, in mid-2007. BACKGROUND Animal health is an increasingly important issue...up of the single market and serious animal health crises. It consists of a series of...
|
|